These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26438155)

  • 1. Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.
    Ni X; Zhang Y; Zennami K; Castanares M; Mukherjee A; Raval RR; Zhou H; DeWeese TL; Lupold SE
    Mol Cancer Ther; 2015 Dec; 14(12):2797-804. PubMed ID: 26438155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.
    Ni X; Zhang Y; Ribas J; Chowdhury WH; Castanares M; Zhang Z; Laiho M; DeWeese TL; Lupold SE
    J Clin Invest; 2011 Jun; 121(6):2383-90. PubMed ID: 21555850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
    Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
    Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
    Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
    Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
    Leach JC; Wang A; Ye K; Jin S
    Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators.
    Shaw BR; Moussa L; Sharaf M; Cheek M; Dobrikov M
    Nucleic Acids Symp Ser (Oxf); 2008; (52):655-6. PubMed ID: 18776550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
    McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
    Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
    Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
    Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
    Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
    Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD
    Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.
    Liu HY; Yu X; Liu H; Wu D; She JX
    Sci Rep; 2016 Jul; 6():30346. PubMed ID: 27456457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
    Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
    Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
    Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
    Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
    Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
    Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
    Liu R; Sun J; Zhang Z; Xu Y
    Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
    Gu F; Langer R; Farokhzad OC
    Methods Mol Biol; 2009; 544():589-98. PubMed ID: 19488725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.